Regional EuroTimes
Date Posted 29/10/2009
Full pipeline for AMD
San Francisco
Several new compounds now in the early clinical testing stage offer the hope of improving on the already impressive results shown with Avastin, Lucentis and related compounds. An interim analysis of 12- and 18-month data presented at the annual AAO conference concluded that fenretinide was well tolerated and showed a trend in favour of reducing lesion size in patients with AMD.
In another presentation, researchers reported that systemic immunosuppressive therapy with daclizumab and sirlolimus appeared to decrease retreatment rates in patients receiving anti-VEGF therapy.
Two other agents, alpha-5-beta-integrin (volociximab) and E10030 appeared safe and potentially effective in phase I studies. Researchers were particularly excited by preliminary results with a complement C3 inhibitor, POT-4. When given by the intravitreal route POT-4 was safe and well tolerated and showed sustained relief properties over a period of months, with improvements seen in chronic macular oedema.
Finally, VEGF-TRAP, an anti-VEGF agent, showed lasting improvements in best-corrected acuity in an 18-month phase II trial.
eTIMES newsletter
eTIMES is a new bi-monthly newsletter with the latest breaking news from the ESCRS and the world of ophthalmology.
eTIMES is a new bi-monthly newsletter with the latest breaking news from the ESCRS and the world of ophthalmology.
Media Guide 2010
Results from our readership survey plus information about advertising in EuroTimes
Results from our readership survey plus information about advertising in EuroTimes
Podcasts
Eye Contact features interviews with key opinion leaders in the world of ophthalmology
Eye Contact features interviews with key opinion leaders in the world of ophthalmology
Tuesday, 07 September 2010
www.eurotimes.org
EuroTimes Breaking News
Faster lasers and better lens surgery are improving options for higher myopes
Date Posted 07/09/2010 MORE HERE...
All-laser LASIK with Ziemer LDV femtosecond and Allegretto Wave Eye-Q provides highly satisfactory visual outcomes
Date Posted 07/09/2010 MORE HERE...
Removing epithelium with laser speeds healing and reduces pain of corneal surface ablation
Date Posted 07/09/2010 MORE HERE...
Ridley Lecture looks at life and death on the posterior capsule
Date Posted 06/09/2010 MORE HERE...
Evidence-based data a top priority for ESCRS
Date Posted 05/09/2010 MORE HERE...
New technology for measuring cornea biomechanics
Date Posted 05/09/2010 MORE HERE...
Industry Breaking News
Rayner launches small-incision IOL injector system
Date Posted 16/08/2010 MORE HERE...
OptiMedica sells retina and glaucoma business to Topcon
Date Posted 16/08/2010 MORE HERE...
Carl Zeiss Meditec announces 20 per cent increase in third quarter revenue
Date Posted 16/08/2010 MORE HERE...
New languages to select from on the Megatron® S4
Date Posted 16/08/2010 MORE HERE...